Companies developing renal denervation systems to treat hypertension are working together with FDA and hypertension experts to map out the future of the technology in the aftermath of the disappointing SYMPLICITY HTN-3 results.
SYMPLICITY HTN-3, the first major sham-controlled trial of renal denervation in patients with uncontrolled hypertension, showed that treatment with Medtronic’s Symplicity did not have a significantly greater effect on systolic blood pressure than a sham procedure in patients with systolic blood pressure over 160